Ghost Tree Capital Stake in Endocyte (ECYT) Has Lowered by $22.10 Million as Market Value Rose; Capital Investment Counsel Has Upped International Business Machs (IBM) Stake

Capital Investment Counsel Inc increased its stake in International Business Machs (IBM) by 27.46% based on its latest 2018Q2 regulatory filing with the SEC. Capital Investment Counsel Inc bought 3,430 shares as the company’s stock rose 0.15% with the market. The institutional investor held 15,922 shares of the computer manufacturing company at the end of 2018Q2, valued at $2.22M, up from 12,492 at the end of the previous reported quarter. Capital Investment Counsel Inc who had been investing in International Business Machs for a number of months, seems to be bullish on the $108.46B market cap company. The stock decreased 3.69% or $4.57 during the last trading session, reaching $119.34. About 7.02 million shares traded or 0.73% up from the average. International Business Machines Corporation (NYSE:IBM) has risen 0.56% since December 8, 2017 and is uptrending. It has underperformed by 15.06% the S&P500. Some Historical IBM News: 17/04/2018 – IBM 1Q EPS $1.81; 24/05/2018 – MariaDB TX 3.0 Delivers First Enterprise Open Source Database to Beat Oracle, Microsoft and IBM; 22/03/2018 – Apple, Google, IBM CEOs Head to China With Trade War Brewing; 24/04/2018 – IBM Raises Dividend to $1.57 Vs. $1.50; 21/03/2018 – IBM launches a cheaper platform for start-ups to build blockchain projects; 30/05/2018 – Graph Blockchain Receives First Payment From IBM; 06/03/2018 – PacketFabric Offers Connectivity to IBM Cloud; 17/04/2018 – IBM Turnaround Questioned on Slower Growth of New Businesses; 17/04/2018 – IBM: Tax Charge Is in Addition to Provisional $5.5 Billion Reported in 4Q; 22/03/2018 – Trianz Wins IBM Excellence Award at Think 2018 for Managed Security Services

Ghost Tree Capital Llc decreased its stake in Endocyte Inc (ECYT) by 77.27% based on its latest 2018Q2 regulatory filing with the SEC. Ghost Tree Capital Llc sold 1.70M shares as the company’s stock rose 31.32% with the market. The hedge fund held 500,000 shares of the health care company at the end of 2018Q2, valued at $6.90 million, down from 2.20 million at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Endocyte Inc for a number of months, seems to be less bullish one the $1.96 billion market cap company. The stock decreased 0.04% or $0.01 during the last trading session, reaching $23.83. About 1.41 million shares traded. Endocyte, Inc. (NASDAQ:ECYT) has risen 1270.29% since December 8, 2017 and is uptrending. It has outperformed by 1254.67% the S&P500. Some Historical ECYT News: 10/04/2018 – Endocyte at Deutsche Bank Health Care Conference May 8; 09/05/2018 – Endocyte 1Q Loss/Shr 16c; 14/05/2018 – VHCP Management Ii Buys New 6.2% Position in Endocyte; 07/05/2018 – Endocyte at Deutsche Bank Health Care Conference Tomorrow; 09/05/2018 – Endocyte Has Cash to Fund Activities Through the Expected End of the VISION Trial and Potential Proof of Concept of Its EC17/CAR T-cell Therapy; 16/04/2018 – ENDOCYTE INC – DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR; 09/05/2018 – Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu; 07/05/2018 – Endocyte Rises for 9 Days: Longest Streak Since IPO; 09/05/2018 – Endocyte Provides First Quarter 2018 Financial Results and Operational Update; 15/03/2018 – ENDOCYTE INC – THREE OF CO’S CURRENT DIRECTORS INFORMED CO THAT THEY WOULD NOT STAND FOR RE-ELECTION AT 2018 ANNUAL MEETING

More notable recent International Business Machines Corporation (NYSE:IBM) news were published by: Seekingalpha.com which released: “IBM + Red Hat: Market Is Assuming A 20% Chance Of Failing The Acquisition – Seeking Alpha” on November 08, 2018, also Fool.com with their article: “Why VMware Stock Jumped 18.4% in November – The Motley Fool” published on December 06, 2018, Seekingalpha.com published: “Crash Protection Kicks In For IBM – Seeking Alpha” on November 25, 2018. More interesting news about International Business Machines Corporation (NYSE:IBM) were released by: Seekingalpha.com and their article: “IBM extends ServiceNow partnership, Cloud Migration – Seeking Alpha” published on November 16, 2018 as well as Fool.com‘s news article titled: “IBM Raises Cash Ahead of Megadeal – The Motley Fool” with publication date: December 07, 2018.

Among 35 analysts covering International Business Machines (NYSE:IBM), 14 have Buy rating, 5 Sell and 16 Hold. Therefore 40% are positive. International Business Machines had 141 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by S&P Research on Thursday, August 27. Oppenheimer initiated the stock with “Perform” rating in Tuesday, August 16 report. Barclays Capital maintained International Business Machines Corporation (NYSE:IBM) rating on Tuesday, July 19. Barclays Capital has “Underweight” rating and $140 target. The stock of International Business Machines Corporation (NYSE:IBM) has “Hold” rating given on Friday, January 19 by BMO Capital Markets. The stock of International Business Machines Corporation (NYSE:IBM) has “Buy” rating given on Wednesday, August 23 by Morgan Stanley. The firm has “Neutral” rating by JP Morgan given on Tuesday, April 19. The firm has “Neutral” rating given on Wednesday, October 17 by Cantor Fitzgerald. The company was maintained on Tuesday, October 20 by Stifel Nicolaus. On Thursday, January 18 the stock rating was maintained by Wedbush with “Hold”. The firm has “Hold” rating by J.P. Morgan given on Friday, January 19.

Since August 3, 2018, it had 5 insider buys, and 1 sale for $426,695 activity. The insider WADDELL FREDERICK H bought 2,153 shares worth $249,722. OWENS JAMES W bought $114,673 worth of stock. Gherson Diane J sold $1.67M worth of stock. $232,838 worth of International Business Machines Corporation (NYSE:IBM) was bought by Swedish Joseph. On Wednesday, October 31 TAUREL SIDNEY bought $495,846 worth of International Business Machines Corporation (NYSE:IBM) or 4,311 shares.

Investors sentiment decreased to 0.9 in Q2 2018. Its down 0.21, from 1.11 in 2018Q1. It is negative, as 62 investors sold IBM shares while 617 reduced holdings. 120 funds opened positions while 493 raised stakes. 489.70 million shares or 2.28% less from 501.15 million shares in 2018Q1 were reported. The United Kingdom-based Pictet Asset Mngmt Limited has invested 0.23% in International Business Machines Corporation (NYSE:IBM). The Massachusetts-based Rhumbline Advisers has invested 0.45% in International Business Machines Corporation (NYSE:IBM). East Coast Asset Mgmt Limited Com holds 0.12% or 5,721 shares in its portfolio. Ballentine Prns Limited Liability Company reported 9,122 shares. Tradition Cap Management Limited Liability has 39,368 shares. Bradley Foster & Sargent Ct invested in 71,493 shares or 0.36% of the stock. Utah Retirement System holds 0.49% or 170,261 shares in its portfolio. Woodmont Inv Counsel Ltd Liability Corporation accumulated 1,982 shares. Atria Limited Company, North Carolina-based fund reported 21,544 shares. Gardner Russo And Gardner Limited Liability Company accumulated 5,503 shares. Cobblestone Cap Advsrs Limited Liability Company has invested 0.1% in International Business Machines Corporation (NYSE:IBM). New Mexico Educational Retirement Board reported 78,947 shares. Tnb accumulated 3,011 shares. Moreover, Hamilton Point Investment Ltd Liability Corporation has 0.11% invested in International Business Machines Corporation (NYSE:IBM) for 1,648 shares. Da Davidson Co stated it has 359,749 shares.

Ghost Tree Capital Llc, which manages about $339.79M US Long portfolio, upped its stake in Mersana Therapeutics Inc by 321,756 shares to 600,000 shares, valued at $10.72 million in 2018Q2, according to the filing. It also increased its holding in Mirati Therapeutics Inc (NASDAQ:MRTX) by 237,500 shares in the quarter, for a total of 500,000 shares, and has risen its stake in Glycomimetics Inc (NASDAQ:GLYC).

Among 6 analysts covering Endocyte (NASDAQ:ECYT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte had 12 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush upgraded the shares of ECYT in report on Tuesday, October 3 to “Outperform” rating. The firm has “Hold” rating given on Friday, June 2 by Cowen & Co. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 4. RBC Capital Markets maintained the shares of ECYT in report on Wednesday, August 5 with “Outperform” rating. Cowen & Co downgraded the stock to “Market Perform” rating in Monday, June 5 report. Wedbush downgraded the shares of ECYT in report on Monday, June 5 to “Neutral” rating. The stock of Endocyte, Inc. (NASDAQ:ECYT) earned “Outperform” rating by Cowen & Co on Tuesday, February 27. The rating was maintained by Wedbush on Monday, July 16 with “Outperform”. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. As per Monday, October 2, the company rating was maintained by Cowen & Co.

Analysts await Endocyte, Inc. (NASDAQ:ECYT) to report earnings on February, 25. They expect $-0.16 earnings per share, up 11.11% or $0.02 from last year’s $-0.18 per share. After $-0.17 actual earnings per share reported by Endocyte, Inc. for the previous quarter, Wall Street now forecasts -5.88% EPS growth.

Since June 12, 2018, it had 0 insider buys, and 13 selling transactions for $2.11 million activity. $92,238 worth of Endocyte, Inc. (NASDAQ:ECYT) was sold by Low Philip S. Armour Alison A. had sold 1,414 shares worth $22,589. Parker Katherine sold $105,316 worth of Endocyte, Inc. (NASDAQ:ECYT) on Friday, October 5. Leamon Christopher P sold $197,058 worth of stock or 13,089 shares. Another trade for 28,146 shares valued at $437,752 was made by Sherman Michael A. on Friday, October 5. Chelius Erik C. sold $70,243 worth of Endocyte, Inc. (NASDAQ:ECYT) on Friday, October 5.

Investors sentiment decreased to 1.69 in Q2 2018. Its down 0.63, from 2.32 in 2018Q1. It turned negative, as 19 investors sold ECYT shares while 20 reduced holdings. 50 funds opened positions while 16 raised stakes. 47.24 million shares or 13.70% more from 41.55 million shares in 2018Q1 were reported. Deutsche Bancshares Ag stated it has 114,227 shares or 0% of all its holdings. 755,618 are owned by Northern Trust Corporation. Gemmer Asset Management Limited Liability Co accumulated 1,500 shares. Tower Research Cap Limited Liability Corporation (Trc) reported 146 shares. Eam Limited Liability Com reported 0.14% stake. Ghost Tree Cap Ltd Liability Company holds 2.03% or 500,000 shares. First Financial In holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 100 shares. Bessemer invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Geode Cap Mgmt Limited Liability Company accumulated 0% or 604,743 shares. Tiaa Cref Invest Limited Liability Corp invested in 142,599 shares. California Public Employees Retirement Systems owns 252,315 shares or 0% of their US portfolio. Morgan Stanley invested 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). 525 are held by Fincl Architects Incorporated. D E Shaw Inc invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Schwab Charles Inv has 138,700 shares.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.